Patents Assigned to Scantibodies Laboratory, Inc.
-
Patent number: 8470543Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values, one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: January 19, 2011Date of Patent: June 25, 2013Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 8329409Abstract: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of non-whole parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of non-whole parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: August 20, 2007Date of Patent: December 11, 2012Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 8298770Abstract: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of non-whole parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of non-whole parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: May 1, 2007Date of Patent: October 30, 2012Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7959920Abstract: The present invention relates to methods of generating anti-PTH antibodies and antibodies generated by the methods of the invention. The anti-PTH antibodies generated by the methods of the invention specifically bind to an epitope on a whole PTH (1-84) which includes one or more N-terminal amino acid residues of the whole PTH. The anti-PTH antibodies generated are useful for detecting whole PTH in a biological sample and for diagnosing parathyroid diseases or disorders.Type: GrantFiled: September 6, 2006Date of Patent: June 14, 2011Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Patent number: 7943323Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: August 15, 2003Date of Patent: May 17, 2011Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7892749Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist.Type: GrantFiled: January 16, 2004Date of Patent: February 22, 2011Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7893021Abstract: The present invention relates to parathyroid hormone (PTH) antagonists. More particularly, the present invention provides for pharmaceutical compositions, kits and combinations comprising the PTH antagonist. The present invention also provides for methods for preventing, treating or delaying a disease or disorder associated with excessive bone mineral, e.g., calcium, loss or for preventing, treating or delaying the effect of a PTH agonist using the PTH antagonist. The present invention further provides for methods for identifying a subject having or at risk of having osteoporosis or decreased bone density, or for identifying a subject in need of PTH antagonist treatment, or for monitoring a subject undergoing treatment for osteoporosis or decreased bone density, by determining and/or monitoring PTH antagonist level or a comparative value between PTH agonist and PTH antagonist.Type: GrantFiled: August 9, 2002Date of Patent: February 22, 2011Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Patent number: 7820393Abstract: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of non-whole parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of non-whole parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: July 10, 2003Date of Patent: October 26, 2010Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7741060Abstract: The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.Type: GrantFiled: November 4, 2008Date of Patent: June 22, 2010Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7723042Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: September 20, 2004Date of Patent: May 25, 2010Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7569025Abstract: The present invention relates to novel methods and devices for treating severe bacterial infections, such as septicemia, using an extracorporeal adsorption container. The device has a solid support disposed and confined within the container and a binding means associated with the solid support that is specific for affixing an infecting bacterium that is causing the severe peripheral bacterial infection and/or bacterial toxins from the bacterium. By passing the infected blood through the container. at least a portion of the infecting bacterium and/or bacterial toxins are removed. The treated blood is returned to the patient.Type: GrantFiled: April 1, 2003Date of Patent: August 4, 2009Assignee: Scantibodies Laboratory, Inc.Inventor: Tom L. Cantor
-
Publication number: 20090142773Abstract: The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.Type: ApplicationFiled: November 4, 2008Publication date: June 4, 2009Applicant: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7541140Abstract: The present invention relates to identifying the risk of a subject developing renal stones utilizing an assessment of PTH agonist, antagonist and/or total PTH levels, optionally together with an assessment of serum and/or urine calcium levels and/or other analytes. The present description further relates to monitoring and guiding treatment for renal stones and kits useful therefore.Type: GrantFiled: June 3, 2005Date of Patent: June 2, 2009Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Publication number: 20090047686Abstract: The present invention relates to methods for producing antibodies that are selective for one or two of the N-terminal amino acid residues of PTH, the antibodies made by such methods, and methods of using them to determine PTH levels while avoiding interference from N-terminally truncated PTH peptides.Type: ApplicationFiled: July 21, 2008Publication date: February 19, 2009Applicant: Scantibodies Laboratory, Inc.Inventor: Thomas L. CANTOR
-
Patent number: 7465703Abstract: The present invention relates to methods and kits useful for guiding the administration of a therapeutic agent in a subject afflicted with, or believed to be afflicted with osteoporosis.Type: GrantFiled: October 1, 2004Date of Patent: December 16, 2008Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Patent number: 7459276Abstract: The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.Type: GrantFiled: September 29, 2003Date of Patent: December 2, 2008Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7056655Abstract: The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.Type: GrantFiled: November 1, 2002Date of Patent: June 6, 2006Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Patent number: 7015005Abstract: The present invention relates to novel methods and devices for detecting non-complexed prostate specific antigen (PSA), which can be used either alone or in conjunction with total PSA tests to identify patients having either benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy or prostatic adenocarcinoma (CAP). In a biological sample, one can find not only non-complexed PSA, but also PSA which has formed a complex with ?1-antichymotrypsin (ACT). The present invention removes or precipitates complexed PSA (PSA-ACT) and ACT from a fluid sample, thereby removing any possible interference due to the binding of complexed PSA to assay reagents.Type: GrantFiled: March 27, 2002Date of Patent: March 21, 2006Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor
-
Publication number: 20050170443Abstract: The present invention relates to detecting an analyte of interest in the presence of other analytes that may be of interest or moieties that interfere with normal assay protocols.Type: ApplicationFiled: October 4, 2004Publication date: August 4, 2005Applicant: Scantibodies Laboratory, Inc.Inventor: Thomas Cantor
-
Patent number: 6923968Abstract: The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID NO:1 [PTH2-84]) and (SEQ ID NO:3 [PTH34-84]) (i.e.Type: GrantFiled: August 10, 2001Date of Patent: August 2, 2005Assignee: Scantibodies Laboratory, Inc.Inventor: Thomas L. Cantor